Haematodermic CD4+CD56+ neoplasm: complete remission after methotrexate-asparaginase treatment.

Clin Exp Dermatol

Department of Dermatology, Claude Bernard University, Lyon Civil Hospices, Hotel-Dieu Hospital, Lyon, France.

Published: July 2009

Haematodermic neoplasm is a recently recognized condition, characterized by tumour cells expressing CD4, CD56 and CD123. This phenotype is strongly suggestive of a plasmacytoid dendritic cell origin. This haematopoietic malignancy is a distinct clinicopathological condition with frequent skin involvement, an evolution toward leukaemia and a rapidly aggressive course. We report the case of a 64-year-old woman who presented with a haematodermic CD4+CD56+CD123+ neoplasm affecting the left cheek; the initial staging was otherwise negative. Despite this early stage of the disease, aggressive treatment including methotrexate-asparaginase and local radiotherapy was proposed as first-line therapy. Complete clinical remission was rapidly reached and the patient was still alive after > 30 months of follow-up. To date there is no consensus on the first-line treatment for such patients but intensive treatment is probably needed immediately even in cases of localized disease. The response obtained with CHOP (cyclophosphamide, doxyrubicin, vincristine, prednisone) or CHOP-like chemotherapy regimens is disappointing. Other regimens, such as those used in acute leukaemia, may improve the outcome of these patients.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2230.2008.03100.xDOI Listing

Publication Analysis

Top Keywords

haematodermic cd4+cd56+
4
cd4+cd56+ neoplasm
4
neoplasm complete
4
complete remission
4
remission methotrexate-asparaginase
4
treatment
4
methotrexate-asparaginase treatment
4
treatment haematodermic
4
haematodermic neoplasm
4
neoplasm recognized
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!